WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017019767) Inhibition of CXCL12 in Cancer Immunotherapy
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/019767 International Application No.: PCT/US2016/044254
Publication Date: 02.02.2017 International Filing Date: 27.07.2016
IPC:
C07K 16/24 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
24
against cytokines, lymphokines or interferons
Applicants: MYOSOTIS, LLC[US/US]; 155 Lambert Drive Princeton, New Jersey 08540, US
Inventors: FEARON, Douglas; US
Agent: WALES, Michele M.; US
Priority Data:
62/197,45527.07.2015US
Title (EN) Inhibition of CXCL12 in Cancer Immunotherapy
(FR) INHIBITION DE CXCL12 DANS L'IMMUNOTHÉRAPIE ANTICANCÉREUSE
Abstract:
(EN) A method is described for increasing effector T-cell accumulation in cancer cell-containing sites of a tumor, comprising administering to a subject in need thereof a pharmaceutically effective amount of a CXCL12-targeted immune response agent. In some embodiments, the CXCL12-targeted immune response agent is administered with another molecule that inhibits or destroys the tumor cell.
(FR) L'invention concerne un procédé permettant d'augmenter l'accumulation de lymphocytes T effecteurs dans des sites contenant des cellules cancéreuses d'une tumeur, consistant à administrer à un sujet qui en a besoin une quantité pharmaceutiquement efficace d'un agent de réponse immunitaire ciblant CXCL12. Dans certains modes de réalisation, l'agent de réponse immunitaire ciblant CXCL12 est administré avec une autre molécule qui inhibe ou détruit la cellule tumorale.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)